The study reported that the GSTP1 rs1695 GG genotype (GG vs. A) was associated with an elevated risk of neurological toxicity during the continuation phase of leukemia therapy (p = 0.006; OR = 2.70; 95%CI = 1.18–6.25) [59]. The gene discussed is GSTP1; the disease is leukemia.